Cognitive Impairment in Schizophrenia Research Study

This Clinical Research Study is to learn if an investigational drug can affect thinking and processing skills in people with schizophrenia.

Fast Facts

cognitive impairment in schizophrenia

have a study partner willing to join

18-50 years old

Conducted in houston, TX

Study Background

Our researchers are investigating ways to improve cognitive impairment (e.g. concentration, memory, reasoning and problem solving) in individuals with schizophrenia. In this study, we will examine the effects of a medication called Iclepertin. 

Your participation may help researchers improve treatment approaches for schizophrenia. If you have a study partner who is willing to join with you, you may qualify for this 8-month study. After the 8-month study, you will have the opportunity to participate in an open-label extension study. Further research today and join our compensated study!

Additional Information

The purpose of this research study is to evaluate whether study medication can improve cognitive impairment (e.g. concentration, memory, reasoning and problem solving) and daily functioning in schizophrenia patients.

You may qualify for this study if you meet the following criteria.

Inclusion Criteria:

  • Diagnosis of schizophrenia
  • 18-50 years old
  • Outpatient and no recent hospitalization
  • Cognitive impairment: difficulty following conversations, expressing yourself, staying focused, remembering instructions, what to say or how to get places, etc.
  • Stable on 1-2 antipsychotics
  • Must have a person willing to be your study partner


Exclusion Criteria:

  • Suicidal behavior in last year
  • In the last 6 months, use of: Clozapine, stimulants, ketamine or esketamine, ECT or modified ECT
  • In the last 12 weeks: Cognitive remediation therapy (CRT) or Initiation/Change in psychotherapy
  • In the last 30 days, use of: tricyclic antidepressants, TMS, neurofeedback, or St. John’s wort
  • Substance use disorder (must have a negative drug screen at baseline)
  • Previously treated with Iclepertin
  • HIV, Hepatitis B or C
  • Malignancy within the past 5 years
  • Allergic to lactose

Once enrolled, this study lasts about 8 months with a visit every 3 weeks (14 total visits). You will be provided with study medication or placebo to take once per day for a 26-week treatment period.

There is no cost for you to participate in this study.